Crystax Pharmaceuticals, S.L.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Crystax Pharmaceuticals, S.L. - overview
Established
2002
Location
Barcelona, -, Spain
Primary Industry
Biotechnology
About
Crystax Pharmaceuticals, S. L. is a company specializing in the development of innovative software solutions for Android developers, offering enhanced tools for native application development. Crystax Pharmaceuticals, S.
L. was founded in 2002 and is headquartered in Barcelona, Spain. The company focuses on providing solutions for the Android development community. In March 2009, Crystax was acquired by Oryzon Genomics.
The firm has completed a total of 3 deals since its inception, with the most recent deal occurring on March 20, 2009. CrystaX specializes in providing the CrystaX NDK, an open-source native development kit designed specifically for Android developers. This toolkit serves as a drop-in replacement for Google's Android NDK, offering enhanced features and compatibility. The CrystaX NDK has been utilized by a variety of commercial and open-source projects since its inception, providing developers with tools to create high-performance Android applications.
The primary use cases it addresses include native code integration, improved performance for resource-intensive applications, and streamlined development processes, making it particularly appealing to developers working on complex Android projects. The CrystaX NDK is distributed globally, reaching developers in various regions, including North America, Europe, and Asia. In 2009, Crystax generated revenue of USD 1,428. 50 mn.
The company operates on a revenue model that combines user donations and fundraising campaigns aimed at supporting ongoing development. Revenue from donations is collected voluntarily, allowing developers to contribute based on the perceived value of the CrystaX NDK. Although the company does not specify pricing plans, it emphasizes community involvement in its funding approach, maintaining the tool's availability for all Android developers. The flagship product, CrystaX NDK, remains central to the company's offerings, catering to a diverse range of developers seeking advanced solutions for Android application development.
Following its acquisition in March 2009, Crystax Pharmaceuticals, S. L. plans to leverage the resources of Oryzon Genomics for future product development. The company aims to design new features for the CrystaX NDK and expand its presence in emerging markets, focusing on developers in Asia and Latin America by 2010.
The recent acquisition provides the capital needed to support these initiatives, ensuring ongoing enhancements to its product offerings.
Current Investors
Najeti Group, Invertec, ICF Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.crystax.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Crystax Pharmaceuticals, S.L. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.